Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2004-02-13
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1469
- Registration Number
- NCT00077636
A Study of Mircera for the Treatment of Anemia in Dialysis Patients
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT00077597
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 627
- Registration Number
- NCT00069108
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Drug: Placebo for bevacizumab 7.5 mg/kgDrug: Placebo for bevacizumab 5 mg/kg
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2035
- Registration Number
- NCT00069095
A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1886
- Registration Number
- NCT00069121
- Locations
- 🇺🇸
New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States
🇺🇸Innovative clinical research institute/American institute of research, Whittier, California, United States
🇺🇸Nh Oncology Hematology, Pa, Hooksett, New Hampshire, United States
Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes
- First Posted Date
- 2003-04-01
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00057317
Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes
- Interventions
- Drug: RO 205-2349
- First Posted Date
- 2003-04-01
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 190
- Registration Number
- NCT00057304
A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: anastrazole (Arimidex®)
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 208
- Registration Number
- NCT00022672
Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5099
- Registration Number
- NCT00045032
- Locations
- 🇦🇺
Saint John of God Hospital, Geelong, Australian Capital Territory, Australia
🇦🇹Landeskrankenhaus Klagenfurt, Klagenfurt, Austria
🇧🇪Centre Hospitalier Notre Dame - Reine Fabiola, Charleroi, Belgium
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 67
- Registration Number
- NCT00022698
- Locations
- 🇺🇸
Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States
🇺🇸Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States
🇺🇸George Washington University Medical Center, Washington, District of Columbia, United States